BioSpace News Archive

Abbott (NYSE: ABT) today announced the U.S. launch of NeuroSphere™ Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians, ensure proper settings and functionality, and receive new treatment settings remotely as needed

Foldax®, Inc. announced that it has been named by Fierce Medtech as one of the 2020 “Fierce 15,” designating it as one of the most promising private companies in the medical technology industry.

Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, today announced that it has entered into an exclusive license and collaboration agreement with Shanghai-based Alpha Biopharma Inc.

Production of monoclonal antibodies targeting these sites is in process. U.S. patent protection has been filed claiming these sites.

Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, and Mercy, one of the nation’s most highly integrated, multi-state health care systems, today announced a definitive agreement for Quest to acquire the outreach laboratory services business of Mercy in an all-cash asset transaction

Zynex, Inc., an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced that its board of directors approved a program to buy back $10.0 million of the Company’s common stock.

Oakland University and William Beaumont Hospitals have extended their affiliation agreement through 2041.

Co-Diagnostics, Inc. (NASDAQ-CM: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will present at the 2021 H.C. Wainwright & Co. Global Life Sciences Conference,

Avail Medsystems, a medical technology company that is pioneering telemedicine for the procedure room, announced that it has been named by Fierce Medtech as one of 2020’s Fierce 15, designating it as one of the most promising private companies in the industry.

Noveome Biotherapeutics, Inc., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity of damaged tissues, has appointed Christopher J. P. Velis to the company’s Board of Directors.